Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update

Aquestive Therapeutics, Inc. (NASDAQ:AQST) was the recipient of a large drop in short interest in October. As of October 31st, there was short interest totalling 10,140,000 shares, a drop of 6.0% from the October 15th total of 10,790,000 shares. Based on an average daily volume of 1,340,000 shares, the days-to-cover ratio is presently 7.6 days.

Analysts Set New Price Targets

AQST has been the subject of a number of research analyst reports. JMP Securities reissued a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Leerink Partners boosted their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday, November 6th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $9.80.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock opened at $4.82 on Wednesday. The business has a 50 day moving average of $4.99 and a 200-day moving average of $3.89. The company has a market capitalization of $439.49 million, a P/E ratio of -10.71 and a beta of 2.82. Aquestive Therapeutics has a 1 year low of $1.73 and a 1 year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $12.69 million. During the same period in the prior year, the business posted ($0.03) EPS. Equities analysts anticipate that Aquestive Therapeutics will post -0.47 EPS for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Financial Advocates Investment Management lifted its stake in shares of Aquestive Therapeutics by 14.7% in the third quarter. Financial Advocates Investment Management now owns 39,000 shares of the company’s stock worth $194,000 after acquiring an additional 5,000 shares during the period. nVerses Capital LLC bought a new position in Aquestive Therapeutics during the 3rd quarter worth approximately $28,000. Charles Schwab Investment Management Inc. lifted its position in shares of Aquestive Therapeutics by 4.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock worth $1,014,000 after purchasing an additional 9,268 shares during the period. SG Americas Securities LLC boosted its stake in shares of Aquestive Therapeutics by 58.9% in the 3rd quarter. SG Americas Securities LLC now owns 25,619 shares of the company’s stock valued at $128,000 after purchasing an additional 9,496 shares during the last quarter. Finally, Victory Capital Management Inc. acquired a new stake in shares of Aquestive Therapeutics during the second quarter worth $27,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.